BGI Hong Kong is the first clinical next-generation-sequencing laboratory operating with the CAP certification in China
BGI announced today that its high-throughput DNA sequencing laboratory in Hong Kong has been accredited by the American College of Pathologists (CAP). The BGI Hong Kong facility is the first clinical next-generation-sequencing laboratory to receive the CAP certification in China, meeting the highest standard in clinical laboratory practices. Complementary to the exiting US FDA - 21 CFR Part 11 compliant laboratory process, and multiple ISO certifications, the CAP certification enables BGI to provide the highest international standard of excellence in quality laboratory practices.
In addition, the BGI Total Quality Program, which includes a 24/7, real-time customer support program, provides industry-leading customer services to our clients. Equipped with the industry’s broadest array of genomics technologies, plus an experienced team of scientists and bioinformaticians, BGI provides the highest-quality data and services for researchers and clinicians from all over the world.
About the College of American Pathologists
The College of American Pathologists (CAP), the leading organization of board-certified pathologists, serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. The CAP offers high-value, integrated solutions and experiences that empower CAP members and customers to achieve excellence in the practice of pathology and laboratory medicine.
BGI was founded in 1999 as a non-profit research organization. Over the years, BGI has grown into a multinational company with significant global operations. Our focus has been centered on improving human health and empowering large-scale human, plant and animal genomics research. Today, by leveraging our R&D, manufacturing and commercial operations around the world, we are dedicated to –
- Providing products and services for a wide-range of life science research and clinical applications
- Enabling large-scale genomics research using high-throughput technology platforms
Bicheng Yang, Ph.D
Director, Communication and Public Engagement